Fabio Blandini
Fabio Blandini
IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (1); University of Pavia (2)
Email verificata su - Home page
Citata da
Citata da
Functional changes of the basal ganglia circuitry in Parkinson's disease
F Blandini, G Nappi, C Tassorelli, E Martignoni
Progress in neurobiology 62 (1), 63-88, 2000
Parkinson’s disease in women and men: what’s the difference?
S Cerri, L Mus, F Blandini
Journal of Parkinson's disease 9 (3), 501-515, 2019
Animal models of Parkinson’s disease
F Blandini, MT Armentero
The FEBS journal 279 (7), 1156-1166, 2012
Glutamate and Parkinson’s disease
F Blandini, RHP Porter, JT Greenamyre
Molecular neurobiology 12, 73-94, 1996
The 6-hydroxydopamine model: news from the past
F Blandini, MT Armentero, E Martignoni
Parkinsonism & related disorders 14, S124-S129, 2008
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
G Ambrosi, S Cerri, F Blandini
Journal of neural transmission 121, 849-859, 2014
Parkinson’s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naive and drug-treated patients
N Kustrimovic, C Comi, L Magistrelli, E Rasini, M Legnaro, R Bombelli, ...
Journal of neuroinflammation 15, 1-17, 2018
Time‐course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6‐hydroxydopamine in the rat: new clues …
F Blandini, G Levandis, E Bazzini, G Nappi, MT Armentero
European Journal of Neuroscience 25 (2), 397-405, 2007
Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat
F Blandini, L Cova, MT Armentero, E Zennaro, G Levandis, P Bossolasco, ...
Cell transplantation 19 (2), 203-218, 2010
Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease
L Cova, MT Armentero, E Zennaro, C Calzarossa, P Bossolasco, G Busca, ...
Brain research 1311, 12-27, 2010
Naproxen sodium in menstrual migraine prophylaxis: A double‐blind placebo controlled study
G Sances, E Martignoni, L Fioroni, F Blandini, F Facchinetti, G Nappi
Headache: The Journal of Head and Face Pain 30 (11), 705-709, 1990
Neural and immune mechanisms in the pathogenesis of Parkinson’s disease
F Blandini
Journal of Neuroimmune Pharmacology 8, 189-201, 2013
Plasma Homocysteine and l-DOPA Metabolism in Patients with Parkinson Disease
F Blandini, R Fancellu, E Martignoni, A Mangiagalli, C Pacchetti, ...
Clinical Chemistry 47 (6), 1102-1104, 2001
Cognitive and affective status in mild hypothyroidism and interactions with l‐thyroxine treatment
G Bono, R Fancellu, F Blandini, G Santoro, M Mauri
Acta Neurologica Scandinavica 110 (1), 59-66, 2004
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
F Blandini, MT Armentero, R Fancellu, E Blaugrund, G Nappi
Experimental neurology 187 (2), 455-459, 2004
SOD1 and DJ‐1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegeneration
P Milani, G Ambrosi, O Gammoh, F Blandini, C Cereda
Oxidative medicine and cellular longevity 2013 (1), 836760, 2013
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease
G Levandis, E Bazzini, MT Armentero, G Nappi, F Blandini
Neurobiology of disease 29 (1), 161-168, 2008
Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease
F Blandini, E Sinforiani, C Pacchetti, A Samuele, E Bazzini, R Zangaglia, ...
Neurology 66 (4), 529-534, 2006
Inefficient DNA repair is an aging-related modifier of Parkinson’s disease
S Sepe, C Milanese, S Gabriels, KWJ Derks, C Payan-Gomez, ...
Cell reports 15 (9), 1866-1875, 2016
Role of autophagy in Parkinson’s disease
S Cerri, F Blandini
Current medicinal chemistry 26 (20), 3702-3718, 2019
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20